Clinical Associate of Medicine, University of Chicago Medicine
Hematology
Dr. Samir D. Undevia, MD
|
|
Give Review
Dr. Samir D. Undevia is an expert in the field of Hematology. He graduated from NYU School of Medicine. He has 3 awards "West Suburban Living Magazine", "CMS Meaningful Use Stage 1 Certification" and "Super Doctor". Samir D. Undevia is also a published physician. He has 24 paper published. The most recent paper is: Correction of the galactocerebrosidase deficiency in globoid cell leukodystrophy-cultured cells by SL3-3 retroviral-mediated gene transfer. He accepts all Medicare patients.
Publications
- A pharmacogenetic study of aldehyde oxidase I in patients treated with XK469.
- Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial.
- Phase I Studies of Sirolimus Alone or in Combination with Pharmacokinetic Modulators in Advanced Cancer Patients.
- Two drug interaction studies of sirolimus in combination with sorafenib or sunitinib in patients with advanced malignancies.
- The quinoxaline anti-tumor agent (R+)XK469 inhibits neuroblastoma tumor growth.
- A phase I study of continuous infusion cilengitide in patients with solid tumors.
- Primary tumor necrosis predicts distant control in locally advanced soft-tissue sarcomas after preoperative concurrent chemoradiotherapy.
- Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment.
- Phase II study of sorafenib in patients with metastatic or recurrent sarcomas.
- A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemia.
- Phase I clinical trial of CEP-2563 dihydrochloride, a receptor tyrosine kinase inhibitor, in patients with refractory solid tumors.
- A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital.
- Dose-ranging study of the safety and pharmacokinetics of atrasentan in patients with refractory malignancies.
- Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan.
- Correction of the galactocerebrosidase deficiency in globoid cell leukodystrophy-cultured cells by SL3-3 retroviral-mediated gene transfer.
- Histologic response of dose-intense chemotherapy with preoperative hypofractionated radiotherapy for patients with high-risk soft tissue sarcomas.
- A phase II study of ixabepilone (BMS-247550) in metastatic renal-cell carcinoma.
- A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine.
- Spinal cord metastasis of a non-neurofibromatosis type-1 malignant peripheral nerve sheath tumor: an unusual manifestation of a rare tumor.
- Pharmacokinetic variability of anticancer agents.
- A phase I and pharmacokinetic study of the quinoxaline antitumour Agent R(+)XK469 in patients with advanced solid tumours.
- R(+)XK469 inhibits hydroxylation of S-warfarin by CYP2C9.
- Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high ...
Schools
New York University School Of Medicine
University Of Chicago Hosps
Procedures Preformed
- Thoracentesis
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- West Suburban Living Magazine
- CMS Meaningful Use Stage 1 Certification
- Super Doctor
Education
-
University of Chicago -
NYU School of Medicine
Hospital
-
University of Chicago Medical Center -
Edward Hospital
Drug Facts
| NPI NUMBER | 1740228857 | |
| NPPES Provider LastName | UNDEVIA | |
| NPPES Provider FirstName | SAMIR | |
| NPPES Provider ZIPCode | 606576708 | |
| NPPES Provider State | IL | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 416.0 | |
| Distinct Opioid Count | 3.0 | |
| Opioid Claim Count | 57.0 | |
| Percent Opioid Claims | 13.7 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1740228857 |
| Last Name Of The Provider | UNDEVIA |
| First Name Of The Provider | SAMIR |
| View All |
Similar Doctors
|
Dr. Joseph J. Kash, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Fariborze B. Barhamand, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Mansoina Baweja, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Alexander Hantel, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
Dr. Dennis Azuma, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Saadia Yunus, DO
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Hassan Pervez, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Cathryn A. Goldberg, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Maria I. Quejada, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. William R. Broderick, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rohit Gupta, MD |
|
|
Dr. Nasir Shahab, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nasir U. Shahab, MD
This Doctor is OpenDoctor Recommended.
|